A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Stopped Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.

Conditions

• Acute Myeloid Leukemia (AML)
• Acute Lymphoblastic Leukemia (ALL)
• Neuroblastoma
• Solid Tumors

Interventions

• DRUG: Idasanutlin
• DRUG: Venetoclax
• DRUG: Cyclophosphamide
• DRUG: Topotecan
• DRUG: Fludarabine
• DRUG: Cytarabine
• DRUG: Intrathecal Chemotherapy

Sponsor

Hoffmann-La Roche